Jurkat Reporter Cell Lines for Immunotherapy Drug Screening
WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening. Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies. Leverage our portfolio of reporter cell lines to accelerate your research!
Learn more about our platform of cell-based phenotypic assays by clicking HERE.
Jurkat reporter cell lines for immunotherapy drug screening
Related Content
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of...
VIEW RESOURCEAsthma is a chronic, lower airway disease characterized by persistent inflammation and hyperreactivity. Asthma involves a complex immune response, with...
VIEW RESOURCE